Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wuzhi Jiaonang (Wuzhi capsule) is a traditional Chinese medicine preparation made from an ethanol extract of the fruit of Schisandra sphenanthera (Nan-Wuweizi). Its main active ingredients include schisandrin, schizandrol B, schisantherin A, schisanhenol, and deoxyschizandrin. The formulation is primarily used in China for liver protection and as an adjunct therapy in organ transplant recipients to treat drug-induced hepatitis. It is known to significantly increase the blood concentration of tacrolimus when coadministered by inhibiting its metabolism—an effect that should be considered due to potential herb-drug interactions[1][2]. The product has been registered for use in China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on wuzhi jiaonang.